Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Interventional × empagliflozin × Clear all

Phase

Phase 2/3 3 Phase 2 2 Phase 4 1 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Cardiotoxicity 1

Interventions

Cisplatin 611 Carboplatin 506 Paclitaxel 489 Radiotherapy 453 Cyclophosphamide 453 Docetaxel 413 Fluorouracil 383 Gemcitabine 363 Doxorubicin 340 Capecitabine 316 Dexamethasone 282 Oxaliplatin 247 Vincristine 235 Leucovorin 234 pembrolizumab 232 Etoposide 230 Bevacizumab 227 Rituximab 209 Prednisone 197 Pemetrexed 180 Cytarabine 179 Drug Therapy 171 Methotrexate 151 Trastuzumab 148 Irinotecan 140 Lenalidomide 123 Filgrastim 118 Nivolumab 112 Chemotherapy, Adjuvant 111 Tamoxifen 108

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05271162 2025-11-21

EMPACT

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 3 Recruiting

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡